Codexis and Arch Pharmalabs expand collaboration

Codexis will offer multiple pharmaceutical intermediates and active pharmaceutical ingredients (API) made with its proprietary biocatalytic processes to both innovator and generic drug manufacturers.

Sales in India will be through its subsidiary, Codexis Laboratories India Private Limited. Arch, which is based in Mumbai, India and has ten facilities throughout the country, will be Codexis’s exclusive manufacturer for these products. The two companies will also co-market products.

Products to be sold under the new collaboration include the full range of intermediates used to manufacture generic atorvastatin, as well as the API itself. Other planned future products include generic intermediates and APIs for montelukast (asthma/allergy) and esomeprazole (ulcers), as well as a key intermediate used in the manufacture of the carbapenem class of antibiotics.

Alan Shaw, president and CEO of Codexis, said: “Codexis and Arch will now offer a broad range of competitively-priced drug ingredients to the global pharmaceutical industry. We believe this collaboration offers a major opportunity for growth.”